<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492973</url>
  </required_header>
  <id_info>
    <org_study_id>LCO.2006.2</org_study_id>
    <nct_id>NCT00492973</nct_id>
  </id_info>
  <brief_title>Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?</brief_title>
  <official_title>Peri-articular Injections Containing a Corticosteroid During Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Lexington Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Joseph's Health Care London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New Lexington Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prior to surgery, a pharmacist will randomly assign participating patients to one of two
      groups. One group will get an injection in the knee during surgery that contains medications
      to limit pain and an antibiotic. A second group will get an injection in the knee during
      surgery that contains the same pain medications and antibiotic along with a corticosteroid to
      control inflammation. Corticosteroids are anti-inflammatory medications, not to be confused
      with muscle-building anabolic steroids you may have heard about in the news. Each patient
      will have an equal chance of being in either of the two groups. This study will test the
      safety and efficacy of methylprednisolone acetate in the treatment of pain and inflammation
      following total knee replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Information collected during your office visits:

      The patient will be asked for a brief medical history so that we may determine if the patient
      can participate in the study. A member of our research team will ask the patient a series of
      questions about his/her knee. The patient will be asked to answer this series of questions a
      total of 4 times over the course of 1 year. Also, we will record how well the patient can
      bend and straighten your knee at these 4 office visits. We will have the patient rate the
      pain in his/her knee and ask the patient if he/she is satisfied with the surgery. If the
      patients have any complications, those will also be recorded. The patient will also have
      X-rays taken of the knee at the postoperative follow-up visits. This is the normal routine
      following total knee replacement. The X-rays will be read by the surgeon to help determine
      the success of the surgery.

      Injection during total knee replacement surgery:

      All patients will receive an injection containing bupivicaine HCl, morphine, epinephrine,
      clonidine, cefuroxime, and normal saline that will be placed directly into the knee during
      surgery. In addition, approximately half of the patients in the study will also receive
      methylprednisolone acetate as part of the injection.

      Information being collected during your hospital stay:

      During the hospital stay, information will be gathered for this study. A physical therapist
      will measure how well the patient can bend and straighten the knee. The amount of pain
      medication that was taken at the hospital will be recorded, and the number of days spent in
      the hospital will also be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee Range of Motion</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee Society Scores</measure>
    <time_frame>3 months postoperative</time_frame>
    <description>The Knee Society Score is on a scale of 0 to 100, with 0 being the worst possible score, and 100 being the best possible score. The Knee Society Score takes into account subjective patient reports of pain and functional ability as well as clinical measures of passive knee range of motion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Pain Medication Taken Per Day</measure>
    <time_frame>Average of 3 days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>6 weeks, 3 months, and 1 year postoperative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complications, Such as Infections, Hospital Readmissions, Manipulations Under Anesthesia, Etc.</measure>
    <time_frame>any point during the first postoperative year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Post-traumatic; Arthrosis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the active comparator group will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Corticosteroid group will have the same medications as the Control Group with the addition of a corticosteroid (methylprednisolone acetate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone acetate</intervention_name>
    <description>Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate</description>
    <arm_group_label>Corticosteroid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>active comparator</intervention_name>
    <description>bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>bupivacaine HCl</other_name>
    <other_name>morphine</other_name>
    <other_name>epinephrine</other_name>
    <other_name>clonidine</other_name>
    <other_name>cefuroxime</other_name>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between ages of 18 and 95

          -  Has elected to undergo total knee replacement

        Exclusion Criteria:

          -  Allergy to any of the medications used in the protocol

          -  History of kidney disease

          -  Rheumatoid arthritis

          -  Any systemic conditions associated with chronic pain

          -  History of deep knee sepsis in the affected extremity

          -  Unable to understand the questions used to obtain the Knee Society Score

          -  Minors and prisoners will be excluded from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian P Christensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New Lexington Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexington Clinic Sports Medicine Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lombardi AV Jr, Berend KR, Mallory TH, Dodds KL, Adams JB. Soft tissue and intra-articular injection of bupivacaine, epinephrine, and morphine has a beneficial effect after total knee arthroplasty. Clin Orthop Relat Res. 2004 Nov;(428):125-30.</citation>
    <PMID>15534532</PMID>
  </reference>
  <reference>
    <citation>Parvataneni HK, Ranawat AS, Ranawat CS. The use of local periarticular injections in the management of postoperative pain after total hip and knee replacement: a multimodal approach. Instr Course Lect. 2007;56:125-31.</citation>
    <PMID>17472300</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <results_first_submitted>October 18, 2012</results_first_submitted>
  <results_first_submitted_qc>October 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2013</results_first_posted>
  <last_update_submitted>October 29, 2013</last_update_submitted>
  <last_update_submitted_qc>October 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>arthroplasty</keyword>
  <keyword>replacement</keyword>
  <keyword>knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Cefuroxime axetil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between 5/1/2006 and 5/1/2008, a total of 101 patients were recruited to participate in the study during a regularly-scheduled office visit at an orthopedic clinic.</recruitment_details>
      <pre_assignment_details>Of the 101 patients that were consented, 11 patients opted to cancel surgery, 11 patients asked to be removed from the study prior to surgery, and 3 patients were excluded as they were found to have existing allergies to study medications. The remaining sample of 76 patients were randomly assigned to one of the two study groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Control Group</title>
          <description>Patients will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
active comparator : bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline</description>
        </group>
        <group group_id="P2">
          <title>Corticosteroid</title>
          <description>Corticosteroid (methylprednisolone acetate)
methylprednisolone acetate : Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38">One patient died of complications related to deep joint sepsis in the early postoperative period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Group</title>
          <description>Patients will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
active comparator : bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline</description>
        </group>
        <group group_id="B2">
          <title>Corticosteroid</title>
          <description>Corticosteroid (methylprednisolone acetate)
methylprednisolone acetate : Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="11.0"/>
                    <measurement group_id="B2" value="65.8" spread="11.1"/>
                    <measurement group_id="B3" value="65.5" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Patients will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
active comparator : bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid</title>
            <description>Corticosteroid (methylprednisolone acetate)
methylprednisolone acetate : Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.9"/>
                    <measurement group_id="O2" value="2.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Knee Range of Motion</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Patients will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
active comparator : bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid</title>
            <description>Corticosteroid (methylprednisolone acetate)
methylprednisolone acetate : Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Range of Motion</title>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.5" spread="10.3"/>
                    <measurement group_id="O2" value="112.4" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Knee Society Scores</title>
        <description>The Knee Society Score is on a scale of 0 to 100, with 0 being the worst possible score, and 100 being the best possible score. The Knee Society Score takes into account subjective patient reports of pain and functional ability as well as clinical measures of passive knee range of motion.</description>
        <time_frame>3 months postoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Patients will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
active comparator : bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid</title>
            <description>Corticosteroid (methylprednisolone acetate)
methylprednisolone acetate : Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Society Scores</title>
          <description>The Knee Society Score is on a scale of 0 to 100, with 0 being the worst possible score, and 100 being the best possible score. The Knee Society Score takes into account subjective patient reports of pain and functional ability as well as clinical measures of passive knee range of motion.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1" spread="11.2"/>
                    <measurement group_id="O2" value="83.3" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of Pain Medication Taken Per Day</title>
        <time_frame>Average of 3 days after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Patients will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
active comparator : bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid</title>
            <description>Corticosteroid (methylprednisolone acetate)
methylprednisolone acetate : Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Pain Medication Taken Per Day</title>
          <units>mg/day morphine equivalant</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" spread="35.1"/>
                    <measurement group_id="O2" value="46.0" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Satisfaction</title>
        <time_frame>6 weeks, 3 months, and 1 year postoperative</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Complications, Such as Infections, Hospital Readmissions, Manipulations Under Anesthesia, Etc.</title>
        <time_frame>any point during the first postoperative year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>Patients will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
active comparator : bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid</title>
            <description>Corticosteroid (methylprednisolone acetate)
methylprednisolone acetate : Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate</description>
          </group>
        </group_list>
        <measure>
          <title>Complications, Such as Infections, Hospital Readmissions, Manipulations Under Anesthesia, Etc.</title>
          <units>Number of participants with complication</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 weeks</time_frame>
      <desc>One patient died 25 days after the surgery as a result of complications associated with deep knee joint sepsis. Two other patients underwent manipulation under anesthesia at a mean of 9 weeks after TKA.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control Group</title>
          <description>Patients will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
active comparator : bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline</description>
        </group>
        <group group_id="E2">
          <title>Corticosteroid</title>
          <description>Corticosteroid (methylprednisolone acetate)
methylprednisolone acetate : Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Manipulation under anesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One patient died 25 days after the surgery as a result of complications associated with deep knee joint sepsis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Cale Jacobs, PhD</name_or_title>
      <organization>Lexington Clinic</organization>
      <phone>859-258-8238</phone>
      <email>cjaco@lexclin.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

